BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 9023364)

  • 1. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G; Schally AV
    Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M; Halmos G; Arencibia JM; Lamharzi N; Schally AV
    Cancer; 1998 Oct; 83(7):1335-43. PubMed ID: 9762934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
    Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
    Qin Y; Halmos G; Cai RZ; Szoke B; Ertl T; Schally AV
    J Cancer Res Clin Oncol; 1994; 120(9):519-28. PubMed ID: 8045917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
    Pinski J; Halmos G; Yano T; Szepeshazi K; Qin Y; Ertl T; Schally AV
    Int J Cancer; 1994 May; 57(4):574-80. PubMed ID: 7910153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K
    Int J Cancer; 1993 Dec; 55(6):963-7. PubMed ID: 7902829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
    Shirahige Y; Cai RZ; Szepeshazi K; Halmos G; Pinski J; Groot K; Schally AV
    Biomed Pharmacother; 1994; 48(10):465-72. PubMed ID: 7858155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
    Hohla F; Schally AV; Kanashiro CA; Buchholz S; Baker B; Kannadka C; Moder A; Aigner E; Datz C; Halmos G
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18671-6. PubMed ID: 18003891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S; Schally AV; Reile H; Halmos G; Szepeshazi K; Groot K; Milovanovic S; Miller G; Yano T
    Acta Oncol; 1994; 33(6):693-701. PubMed ID: 7946450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
    Miyazaki M; Lamharzi N; Schally AV; Halmos G; Szepeshazi K; Groot K; Cai RZ
    Eur J Cancer; 1998 Apr; 34(5):710-7. PubMed ID: 9713279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
    Bajo AM; Schally AV; Krupa M; Hebert F; Groot K; Szepeshazi K
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3836-41. PubMed ID: 11891317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
    Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
    Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
    Szepeshazi K; Schally AV; Halmos G; Lamharzi N; Groot K; Horvath JE
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10913-8. PubMed ID: 9380734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
    Rick FG; Buchholz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Aigner E; Perez R; Seitz S; Block NL; Hohla F
    Cell Cycle; 2012 Jul; 11(13):2518-25. PubMed ID: 22751419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.